Novartis Cosentyx® shows clinically meaningful symptom ...

Basel, September 10, 2022 — Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx® ( ...

Novartis' Cosentyx shows sustained improvements in signs and ...

By Week 3, half of those (50%) treated with Cosentyx reported clinically meaningful improvements in pain of over 20%, as measured by Visual Analogue Scale (VAS)[ ...

Patients with hidradenitis suppurativa experienced sustained ...

“These data show that Cosentyx could provide meaningful and long-lasting improvement of HS symptoms. Based on these encouraging data, we hope to ...

Novartis receives European approval for Cosentyx® as first and only ...

Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 ...

Novartis data show Cosentyx® treatment results in rapid and ...

Wallman JK et al. Secukinumab provides sustained improvement in signs and symptoms of psoriatic arthritis in patients with and without enthesitis: 2 year pooled ...

Novartis announces study data demonstrating Cosentyx® reduced ...

EAST HANOVER, N.J., Nov. 7, 2017 /PRNewswire/ -- Novartis announced today results from the FUTURE 5 study showing Cosentyx® (secukinumab) reduced the signs and ...

Novartis Cosentyx® gains positive CHMP opinion for hidradenitis ...

Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 5 ...

Novartis presents new Cosentyx data showing long-lasting efficacy ...

Cosentyx is also the only IL-17A inhibitor indicated for ankylosing spondylitis (AS), PsA, and psoriasis[4] - this is significant as up to eight in 10 patients ...

Novartis PREVENT data show Cosentyx® helps patients realize ...

The study found patients treated with Cosentyx 150 mg showed significant and sustained improvements in signs and symptoms of non-radiographic axial ...

Novartis Cosentyx® shows early synovitis reduction in patients with ...

The use of a standardized ultrasound synovitis score (GLOESS) as the primary endpoint showed objectively the significant benefit of Cosentyx® ...

Novartis' Cosentyx® shows almost all psoriasis patients rapidly ...

Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause · have any of the conditions or symptoms listed ...

New two year data for Novartis' Cosentyx® show sustained ...

In addition, Cosentyx showed a sustained response in improvements of signs and symptoms, physical function and quality of life in AS patients over two years[2].

Novartis Cosentyx® data at AAD VMX shows improvement in skin ...

“Living with moderate to severe plaque psoriasis can have a significant impact on children's physical and emotional well-being, and these findings support the ...

Novartis seeks leadership with Cosentyx® showing no radiographic ...

The new data also confirm sustained improvement in signs and symptoms in almost 80 percent of patients, while Cosentyx delivers a favorable and consistent ...

FDA approves Novartis Cosentyx® as the first new biologic ...

Cosentyx is a proven medicine and has been studied clinically for more than 14 years. The medicine is backed by robust evidence, including 8 ...

Novartis' Cosentyx Shows To Ease Symptoms In Painful Skin ...

Novartis AG (NYSE: NVS) announced the results from two Phase 3 studies (SUNSHINE and SUNRISE) of Cosentyx (secukinumab) in ...

Novartis' Cosentyx shows continued improvement in hidradenitis ...

Novartis' Cosentyx (secukinumab) has demonstrated sustained efficacy and symptom improvement in patients with the inflammatory skin disease hidradenitis ...

Patients With Hidradenitis Suppurativa Treated With Novartis ...

Patients With Hidradenitis Suppurativa Treated With Novartis' Cosentyx Show Improvement ... Results of 2 phase 3 clinical trials demonstrate ...

Secukinumab improves active psoriatic arthritis symptoms and ...

Objectives To evaluate the effect of subcutaneous (s.c.) secukinumab, an interleukin-17A inhibitor, on clinical signs and symptoms and radiographic ...

Positive Results from 2 Novartis Trials for HS Treatment

Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal phase III trials.